ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analyst consensus: Hold — five analysts cover ARS Pharmaceuticals (1 sell, 1 hold, 3 buy) with an average 1‑year price target of $28.25.
• Shares traded at $8.14 (down 0.6%) with a market cap of about $808 million, a negative P/E (-4.67), and a 52‑week range of $6.66–$18.90; the 50‑ and 200‑day moving averages are $8.90 and $9.63, respectively.
• In the latest quarter ARS reported EPS of -$0.42 (in line with estimates) and revenue of $28.09M (above the $25.58M expectation), though the company remains unprofitable with a net margin of -203.25% and institutional ownership of ~68%.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.25.

Several equities analysts have weighed in on the company. Northland Securities began coverage on ARS Pharmaceuticals in a research note on Thursday. They issued an "outperform" rating and a $25.00 price objective on the stock. Zacks Research upgraded ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st.

ARS Pharmaceuticals Stock Down 0.6%

SPRY traded down $0.05 during trading on Thursday, reaching $8.14. 241,960 shares of the stock traded hands, compared to its average volume of 1,461,906. The stock has a market cap of $808.30 million, a price-to-earnings ratio of -4.67 and a beta of 0.86. ARS Pharmaceuticals has a fifty-two week low of $6.66 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 1.47, a current ratio of 7.28 and a quick ratio of 7.06. The stock's 50-day simple moving average is $8.90 and its two-hundred day simple moving average is $9.63.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.42). ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%.The firm had revenue of $28.09 million during the quarter, compared to analysts' expectations of $25.58 million. As a group, equities research analysts expect that ARS Pharmaceuticals will post -0.55 EPS for the current year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SPRY. CWM LLC boosted its holdings in ARS Pharmaceuticals by 243.7% during the third quarter. CWM LLC now owns 2,547 shares of the company's stock valued at $26,000 after purchasing an additional 1,806 shares in the last quarter. Torren Management LLC acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company's stock valued at $56,000 after purchasing an additional 982 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $65,000. Finally, Russell Investments Group Ltd. boosted its holdings in ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company's stock valued at $67,000 after purchasing an additional 4,427 shares in the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.